Advertisement

Current Respiratory Care Reports

, Volume 1, Issue 4, pp 224–232 | Cite as

Connective tissue disease-associated interstitial lung disease: a review

  • Markus Gutsche
  • Glenn D. Rosen
  • Jeffrey J. Swigris
Interstitial Lung Disease (G Tino, Section Editor)

Abstract

Interstitial lung disease (ILD) is commonly encountered in patients with connective tissue diseases (CTD). Besides the lung parenchyma, the airways, pulmonary vasculature and structures of the chest wall may all be involved, depending on the type of CTD. As a result of this so-called multi-compartment involvement, airflow limitation, pulmonary hypertension, vasculitis and extrapulmonary restriction can occur alongside fibro-inflammatory parenchymal abnormalities in CTD. Rheumatoid arthritis (RA), systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), Sjögren’s syndrome (SjS), systemic lupus erythematosus (SLE), and undifferentiated connective tissue disease (UCTD), as well as mixed connective tissue disease (MCTD), can all be associated with the development of ILD. Nonspecific interstitial pneumonia (NSIP) is the most commonly observed histopathological pattern in CTD-ILD, but other patterns, including usual interstitial pneumonia (UIP), organizing pneumonia (OP), diffuse alveolar damage (DAD) and lymphocytic interstitial pneumonia (LIP), may occur. Although the majority of patients with CTD-ILD experience stable or slowly advancing ILD, a small yet significant group exhibits a more severe and progressive course. Randomized placebo-controlled trials evaluating the efficacy of immunomodulatory treatments have been conducted only in SSc-associated ILD. However, clinical experience suggests that a handful of immunosuppressive medications are potentially effective in a sizeable portion of patients with ILD caused by other CTDs. In this manuscript, we review the clinical characteristics and management of the most common CTD-ILDs.

Keywords

Connective tissue disease Interstitial lung disease Autoimmune disease Pulmonary fibrosis Rheumatoid arthritis Dermatomyositis Polymyositis Sjogren's syndrome Progressive systemic sclerosis Systemic lupus erythematosus Mixed connective tissue disease Undifferentiated connective tissue disease Lung-dominant connective tissue disease 

Introduction

Lung involvement is common in connective tissue diseases (CTDs) and can lead to significant morbidity and shortened survival. Depending on the underlying CTD, various thoracic compartments can be involved simultaneously; although, for this review, we will focus on the parenchymal changes of CTD-associated interstitial lung disease (CTD-ILD). Most CTD-ILD presents with a dry cough, gradually progressive dyspnea and a restrictive ventilatory defect on pulmonary function tests (PFTs). Many patients diagnosed with CTD-ILD have a classifiable CTD at the time ILD is recognized; however, in up to 25 % of cases, a constellation of clinical and serological findings suggest, but are not entirely diagnostic of, a classifiable CTD. Patients in such a scenario have been labeled with “undifferentiated” CTD (UCTD), lung-dominant CTD and autoimmune-featured ILD by various investigators [1••, 2]. Lung disease can also predate extrapulmonary CTD manifestations by several years, thus making the distinction between CTD-ILD and an idiopathic interstitial pneumonia (IIP) difficult [3]. Below, we provide a general description of the physiological, histological and radiological findings and management features of CTD-ILD and proceed to highlight some of the unique and important aspects of ILD in the context of each individual CTD.

Clinical features of CTD-ILD

Pulmonary function testing (PFT)

The classic PFT pattern observed in CTD-ILD is a restrictive ventilatory defect and reduced diffusion capacity (DLco). However, when other thoracic compartments such as airways, vasculature or chest wall are involved (as may occur in CTD), clinicians should be aware that a different constellation of PFT-abnormalities can arise. For example, a disproportionate reduction in DLco may signify ILD with coexistent emphysema or pulmonary hypertension [4••], or a significant reduction in lung volumes with relatively preserved DLco should raise suspicion for extrapulmonary restriction (e.g., chest wall skin thickening, respiratory muscle weakness or kyphoscoliosis).

Histopathological patterns

Except for rheumatoid arthritis (RA), in which usual interstitial pneumonia (UIP)-pattern pathology is more common, the nonspecific interstitial pneumonia (NSIP) pattern of lung injury is most common across all CTD-ILD [5, 6•] Compared with cases in which UIP-pattern injury is idiopathic (i.e., idiopathic pulmonary fibrosis [IPF]), CTD-associated UIP (CTD-UIP) has fewer fibroblastic foci, smaller honeycomb cysts, a greater number of germinal centers and more inflammation [7]. Although results are conflicting, some studies suggest patients with CTD-UIP have a better prognosis than IPF-patients. Also a matter of debate, some studies suggest no difference in prognosis between CTD-UIP and CTD-NSIP, contrasting with what is known about the difference in prognosis between idiopathic NSIP and IPF [6•, 8, 9] Less commonly encountered injury patterns of CTD-ILD include organizing pneumonia (OP)—although OP not uncommonly occurs as a secondary feature in patients with CTD—diffuse alveolar damage (DAD), lymphocytic interstitial pneumonia (LIP) and desquamative interstitial pneumonia (DIP).

Because of conflicting study results, many clinicians are uncertain about the utility of surgical lung biopsy (SLBx) in their patients with CTD-ILD. On the one hand, many clinicians believe that, among patients with CTD-ILD, UIP-pattern histology confers a worse prognosis than NSIP-pattern histology. Those in this camp would have their CTD-ILD patients undergo SLBx, because the results could better define disease trajectory. On the other hand, clinicians not using SLBx in their patients with CTD-ILD are either unconvinced that the histological pattern trumps pulmonary physiology in determining prognosis, or more likely, do not expect the results to change management: they plan to treat (or perhaps already are treating) with immunosuppressive medications, and the SLBx pattern would not affect their choice of therapeutic agent or anticipated duration of therapy. When an etiology for the ILD other than CTD (e.g. hypersensitivity pneumonitis) is seriously considered, or when imaging features suggest malignancy or infection (e.g. progressive nodules, cavitation, consolidation, pleural thickening or effusion), there is greater consensus about the utility of SLBx in this patient population.

High-resolution computer tomography (HRCT) findings

Most parenchymal abnormalities in CTD-ILD are easily appreciated with HRCT and commonly described using terminology applied to IIPs (Figs. 1 and 2). While each CTD demonstrates a predilection for a certain pattern of parenchymal involvement, significant overlap exists (Table 1) [10••, 11]. Overall, a radiographic NSIP-pattern is found most commonly in CTD-ILDs, and is characterized by intralobular and interlobular reticular opacities in a predominantly subpleural and basilar distribution. Ground-glass opacities are usually considered to represent a higher degree of cellularity and suggest the disease is potentially more responsive to treatment, although in some cases this is not true. Subpleural sparing—an opacity-free, thin rim of parenchyma directly adjacent to the pleura in the posterior zones of the lung bases—hints at an underlying NSIP-pattern of lung injury and argues against the UIP-pattern. Reticulation, traction bronchiectasis and honeycombing reflect fibrotic changes and more advanced ILD. Abnormalities in other thoracic structures (e.g., esophageal or pulmonary artery dilatation)—hinting at the presence of multi-compartment involvement—should raise suspicion for the presence of a CTD [12••, 13••].
Fig. 1

Slice from a HRCT scan from a 65-year-old man with rheumatoid arthritis. Note the honeycombing characteristic of a radiographic UIP-pattern

Fig. 2

Coronal view slice from a HRCT scan from a 58-year-old woman with dermatomyositis. Notice the ground-glass opacities and traction bronchiolectasis characteristic of mixed cellular and fibrotic NSIP

Table 1

Radiological pattern in CTD-ILD [10, 11]

 

NSIP

UIP

OP

PH

DAD

LIP

Hemorrhage

Airways disease

RA

+

++++

++

+

+

+

 

++++

SSc

++++

+

+

+++

+

   

PM/DM

++++

+

++++

 

+

   

SjS

++

+

+

+

+

++++

 

+++

MCTD

++

+

+

+

+

   

SLE

++

+

+

+

++

+

++

+

The number of ‘+’ signs indicates the frequency of observed injury pattern, i.e., ++++ = very common or clinically prominent manifestation, + = less common, empty cells = rare or not described in this disease; RA=rheumatoid arthritis; SSc=systemic sclerosis; PM/DM=polymyositis/dermatomyositis; SjS=Sjögren’s syndrome; MCTD=mixed-connective tissue disease; SLE=systemic lupus erythematosus

Serological studies

Serum auto-antibodies will be explored in the sections covering each of the CTDs below [13••].

General strategies in the management of CTD-ILD

Not every patient with CTD-ILD requires treatment; thus, it is important to distinguish trivial disease (with low likelihood for progression) from clinically significant ILD. HRCT and PFTs are most helpful in objectively determining disease severity and its course over time, but strong consensus regarding which patients to treat, when and for how long has not been achieved for CTD-ILD. In our experience, patients with disease extent <10 % on HRCT and/or forced vital capacity (FVC) > 75 % and/or DLco > 65 %, in the absence of respiratory symptoms, can be carefully monitored every 3–6 months for evidence of progression. Since immunomodulatory medications are associated with significant adverse effects, we reserve treatment for those cases with severe, extensive or progressive disease. Various regimens have been used to treat CTD-ILD, but the only large-scale, randomized trials have been conducted to examine the effectiveness of cyclophosphamide (or cyclophosphamide followed by azathioprine) in patients with SSc-ILD [14, 15]. Data for other immunomodulatory drugs (including azathioprine, mycophenolate mofetil and tacrolimus) stem from case reports and observational case series [16-18]. We typically evaluate the response to therapy every three months. A favorable response may be defined as improvement in symptoms and functional capacity, or disease extent on HRCT or pulmonary physiology; however, in this challenging spectrum of diseases, halting progression and maintaining stability should also be considered a success. As mentioned above, there are a number of questions that remain unanswered about the treatment of CTD-ILD, so this is an area ripe for investigation.

ILD in specific CTDs

Rheumatoid arthritis (RA)

RA is the most common CTD and is characterized by an erosive inflammatory polyarthropathy with symmetrical arthritis and a range of pulmonary manifestations. While RA occurs more commonly in females (female to male ratio 3:1), RA-ILD is more frequent in males. The prevalence of RA-ILD varies from 5–58 %, depending on the case definition for ILD [19-21]. Smoking is a risk factor for RA-ILD, and emerging data suggest that cigarette smoke exerts its effects by promoting the citrullination of various proteins in the lung. In fact, theories have arisen that seropositive RA “starts” in the lung [22, 23]. Severe ILD may occur when joint disease is mild or well controlled with therapy—there appears to be no reliable correlation between the extent or severity of the joint disease and the development or progression of ILD in patients with RA.

RA-ILD manifests most commonly in the UIP-pattern, and less commonly with NSIP-pattern injury. However, clinicians caring for patients with RA must keep in mind that medications used to treat extrapulmonary disease (e.g., methotrexate) can cause ILD and predispose to opportunistic infections. Thus, a detailed drug history is crucial in all patients with CTD-ILD. A temporal relationship between drug initiation and symptom onset and then improvement after withdrawal can point toward drug-induced lung disease. However, delayed reactions or continued progression despite stopping the medication can occur, making the differentiation between drug-induced ILD and worsening RA-ILD challenging. In this situation, diagnostic BAL can help to exclude infectious etiologies, while BAL-lymphocytosis and/or eosinophilia with or without peripheral blood eosinophilia can further support the diagnosis of drug-induced ILD. Some of the most commonly prescribed medications implicated in pulmonary toxicity include methotrexate, leflunomide, gold salts, sulfasalazine, and anti-tumor necrosis factor (anti-TNF) antibodies [24-28] A helpful online tool listing all medications associated with pulmonary toxicity in further detail can be found at pneumotox.com [29••]. We advocate against the use of drugs with high rates of pulmonary toxicity in RA patients with pre-existing lung disease.

Due to the absence of randomized controlled trials, the treatment of RA-ILD remains entirely empirical. High-dose corticosteroids are often used in patients with potentially reversible patterns such as OP or those with flares of RA-ILD. In addition, cyclophosphamide, azathioprine, cyclosporine or mycophenolate have been used as steroid sparing agents or in steroid-refractory cases [17, 18, 30-32]. In our experience, biologic agents control the joint disease very well, but have minimal effect on ILD. Lung transplantation is offered by certain centers to RA-ILD patients with limited joint disease and relatively preserved functional status.

Systemic sclerosis

Systemic sclerosis is the CTD with the largest percentage of patients afflicted with ILD (40–80 %, depending on method of ascertainment). Along with pulmonary hypertension (PH), ILD is a major cause of death in this disease [33•, 34]. The frequency of ILD depends on ethnicity, autoantibody pattern, and less so on the extent of skin disease. Most patients with SSc have high titers of antinuclear antibodies (ANA)—most often in a nucleolar pattern. Three antibodies with the highest specificity for SSc include antibodies against anti-RNA polymerase III (Pol3), anticentromere antibodies (ACA) and antibodies against topoisomerase (anti-Scl70). Anti-Scl70 antibodies are strongly associated with ILD [36]. Although ACA are protective from significant ILD, patients with ACA carry a high risk for the development of PH later in the course of the disease [35•]. The Pol3 antibody is seen with diffuse skin disease and renal crisis, but is rarely associated with significant lung fibrosis [35•].

The majority of patients with SSc-ILD have NSIP-pattern injury [36]. Less commonly, a UIP-pattern is observed, and other histophatological patterns (e.g., OP or DAD) are very rare. As with other CTD-ILD patients, a subset with SSc-ILD is believed not to require treatment. Some experts adhere to using a staging system to help determine which SSc-ILD patients to treat with immunomodulatory therapy: Goh and colleagues observed that patients with lung involvement greater than 20 % on HRCT and a FVC < 70 % of predicted were most likely to progress without therapy [37]. Such patients with more severe disease are often treated aggressively.

Two randomized placebo controlled trials, the Scleroderma Lung Study (SLS) and the Fibrosing Alveolitis Scleroderma Trial (FAST), evaluated cyclophosphamide (given orally at 2 mg/kg for one year in SLS, and intravenously at a dose of 600 mg/m2 monthly for six months, followed by oral azathioprine for the following six months in FAST) for SSc-ILD [14, 15]. Results from both studies demonstrated a slower decline in FVC in the cyclophosphamide group compared with placebo. Intravenous administration of cyclophosphamide was associated with a lower rate of gonadal failure, severe infections and bone marrow toxicity compared to oral medication, presumably due to higher cumulative dose achieved with daily oral medication [38]. Six months after discontinuation of immunosuppression, the improvements in FVC waned to baseline, suggesting prolonged immunomodulatory therapy may be required to maintain stability of lung function [39].

Whether there is a causal relationship between ILD and esophageal dysmotility/gastroesophageal reflux disease (GERD)/microaspiration is unclear, but we believe aggressive treatment of these abnormalities in patients with SSc-ILD (and any other ILD patient with them) is warranted. Co-management with gastroenterology can be helpful.

Polymyositis and dermatomyositis

Both polymyositis (PM) and dermatomyositis (DM) share the diagnostic criteria of symmetrical proximal muscle weakness, raised serum muscle enzymes, and muscle biopsy and electromyography results consistent with myositis. In addition, DM requires the presence of certain skin manifestations (e.g., heliotrope rash and Gottron’s sign) to fulfill diagnostic criteria [40, 41•]. In amyopathic DM, classical skin findings of DM are present without muscle involvement [42]. Overall, pulmonary disease is present in one-third to two-thirds of patients and is a significant cause of mortality in PM/DM [43•].

In patients with clinically significant disease, two main types of clinical presentations have been observed. The first is characterized by subacute onset of dyspnea and widespread basilar predominant ground-glass opacities and consolidation against a background of reticulation with traction bronchiectasis on CT [44•]. Many patients presenting this way progress significantly over a few weeks to months and are refractory to therapy. Histopathologically, a DAD pattern atop both OP and NSIP has been described in this setting [45, 46]. The other form of presentation is more common and involves an insidious onset and slowly progressive dyspnea. A combined pattern of NSIP and OP are observed on HRCT and in histopathological specimens [47-49]. Other patients with PM/DM can present with a UIP-pattern of lung injury.

As with most CTDs, lung involvement in PM/DM may occur before, after or at the same time of the development of extrapulmonary manifestations [50, 51]. Risk factors for the development of PM/DM-ILD include a higher age (>45), joint involvement [51, 52], and in particular, the presence of aminoacyl-tRNA synthetase (i.e., anti-synthetase or AS) antibodies. The most commonly identified AS antibody is directed against anti-histidyl-tRNA synthetase (anti-Jo1) and is present in 25–40 % of all patients with PM/DM [53•, 54, 55] and in 30–75 % of those cases with ILD [49, 52, 56-58]. Other less commonly found antibodies include anti-PL-7, -PL-12, -OJ, -EJ, -KS and -Zo [51, 55, 59]. The combination of arthritis, myositis, anti-synthetase antibodies and ILD constitutes the anti-synthetase syndrome. Raynaud’s phenomenon, “mechanic’s hands” (dry, rough, fissured skin of the hands, particularly on the thenar side of the index finger and the finger tips) and fever, while not part of the diagnostic criteria of anti-synthetase syndrome, are other findings frequently encountered [59]. It is not entirely clear whether AS antibodies are pathogenic or merely disease markers. In addition, it is unknown whether the different AS antibodies portend different clinical phenotypes.

As with most other CTDs, no definitive recommendations for the treatment of PM/DM-associated ILD exist due to the lack of randomized clinical trials. High-dose oral prednisone is often used as first-line therapy in PM/DM-associated ILD. In the US, azathioprine and mycophenolate are the most frequently used immunomodulatory agents for PM/DM-ILD; however, there are case reports and case series suggesting a role for the calcineurin antagonists [60, 61]. In severe, rapidly progressive disease, intravenous cyclophosphamide in conjunction with high-dose methylprednisone has been used [62, 63]. Rituximab has been tried in patients who failed to respond to conventional immunosuppressive regimens or who presented with rapidly progressive DAD [64, 65]. In addition to treating refractory myositis, intravenous immunoglobulins have been used with some success to treat rapidly progressive ILD [66]. In PM/DM, the risk of malignancy is increased and screening for occult neoplasm should be considered, particularly in patient without AS antibodies.

Sjögren’s syndrome

In 1933 Sjӧgren introduced the term “keratoconjunctivitis sicca”, also referred to as “sicca complex” to describe a syndrome characterized by dry eyes and dry mouth [67]. Sjӧgren’s syndrome (SjS) is a chronic inflammatory condition characterized by lymphocytic infiltration of exocrine glands (including salivary and lacrimal glands), and other structures, including the lungs. It can occur either in isolation, when it is referred to as primary SjS, or as a secondary phenomenon in the setting of another established CTD, in which case it is termed secondary SjS [68•]. The primary form displays more severe exocrine dysfunction, including renal tubular disorder, neurological involvement and vascular disorders (Raynaud’s phenomenon and vasculitis) [69]. In the absence of a salivary gland biopsy demonstrating focal lymphocytic sialoadenitis, the presence of “keratoconjunctivitis sicca” and anti-nuclear antibodies against ribonucleoproteins Ro/SSA and La/SSB is required to fulfill diagnostic criteria in both primary and secondary SjS [69]. Polyclonal hypergammaglobulinemia, elevated sedimentation rate and other autoimmune antibodies (e.g., rheumatoid factor) can be found with varying frequency in SjS and are nonspecific [70, 71]. Patients with SjS are at increased risk for pulmonary and other lymphomas [72•, 73].

Although restriction and reduced DLco have been found in 17–37.5 % of patients with SjS, clinically significant ILD is rare, and in most cases SjS-ILD follows a mild and self-limited course [74, 75]. Respiratory symptoms mostly relate to dry mucous membranes predisposing patients with SjS to hoarseness and dry cough (due to xerotrachea). Patients with SjS are at increased risk of respiratory tract infections, due to impaired immune function of the mucosal barrier lining the airway epithelium. Exertional dyspnea is reported by some patients [75, 76]. Pleuritis, PAH, middle lobe syndrome and shrinking lung syndrome have been described in SjS rarely [77•, 78-80].

Authors of older series reported LIP as the most common histopathological pattern in patients with SjS, but more recent studies have revealed a higher frequency of NSIP-pattern injury in this disease [81•, 82]. This finding is likely based on the reclassification of many cases as cellular NSIP, which in the past would have been interpreted as LIP [83]. Other less commonly observed patterns include OP and UIP. In patients with SjS-ILD, HRCT and histopathological findings correlate well with each other, so SLBx is usually not recommended [82, 84, 85]. However, radiographic features suggestive of lymphoma (see below) require thorough investigation [86•]. Ground-glass opacities and thin-walled cysts in a peri-bronchovascular distribution can occur with LIP. Centrilobular nodules are noted with LIP or lymphocytic bronchiolitis. Pulmonary lymphoma accounts for approximately 20 % of all SjS-associated lymphomas [73, 74]. Both LIP and pulmonary lymphoma have overlapping features, including ground-glass opacification, small nodules and hilar-mediastinal lymphadenopathy. Consolidation, large nodules measuring more than 10 mm, as well as pleural effusions, are more common in lymphoma, whereas cysts are more frequently observed in LIP [87].

Unclassifiable connective tissue disease

A large minority of patients with ILD do not fulfill the diagnostic criteria for any specific CTD, but display features including positive serologies and systemic extrapulmonary manifestations that are reminiscent of an underlying autoimmune disease. Such patients have been labeled as having an “autoimmune flavor” [87]. Over the course of follow-up, a number of these patients go on to develop clinical and serological characteristics that fulfill diagnostic criteria for a specific CTD [88•]. Ongoing investigations aim to determine how best to follow, treat and conduct research in this interesting population. Such patients are different from those with anti-U1 RNP antibodies and features of more than one specific CTD who have mixed connective tissue disease (MCTD)—a specific CTD [89•]. While a large number of patients with MCTD have pulmonary involvement, most have relatively mild disease, and many are asymptomatic [90]. Pleural effusions, ILD consistent with NSIP and sometimes UIP, and PAH, either as a result of CTD-ILD or in isolation, have all been described in MCTD [91•, 92].

Systemic lupus erythematosus

SLE is a multisystem disorder afflicting joints, skin, kidneys, central nervous system, and serosal surfaces of internal organs including heart and lungs. The disease is more prevalent in women of reproductive age and African Americans [93]. Almost all patients are anti-nuclear antibody (ANA) positive [94, 95]. Four or more criteria are required to establish the diagnosis [96•]. Interestingly, these criteria do not include any pulmonary manifestations, except for pleuritis. Although respiratory symptoms associated with SLE are often absent, abnormal PFT and HRCT findings are common, and the prognosis is significantly worse in patients experiencing pulmonary complications [97, 98•, 99, 100].

While trivial lung disease is present in one third of patients, clinically significant disease afflicts only 3–8 % of the lupus population [101, 102]. In some cases, acute lupus pneumonitis (ALP) with a DAD-pattern heralds the development of ILD [103]. Similar to most other CTD-ILDs, NSIP is the most commonly observed histopathological pattern, but LIP, OP and UIP have all been described [98•, 104-106]. Diffuse alveolar hemorrhage (DAH) and ALP are characterized by acute onset of dyspnea with fever, cough and in the case of DAH, sometimes hemoptysis. A sudden decrease in hemoglobin is highly suggestive of DAH [99, 104, 107, 108]. Approximately one-half of patients with DAH require mechanical ventilation. An increasingly bloody return on BAL is diagnostic and supported by high counts of red blood cells and hemosiderin-laden macrophages on the differential cell count. A neutrophilic capillaritis and alveoli filled with red blood cells are seen on histopathology of lung tissue from patients with DAH [109]. In ALP, the histopathological picture resembles DAD, but without hemorrhage or capillaritis [99]. Both ALP and DAH present with diffuse, bilateral ground-glass opacities on HRCT. In this setting pulmonary edema, drug reactions as well as infection all need to be excluded.

Due to the high incidence of infections in SLE, broad-spectrum antibiotic therapy should be started empirically without delay, while infectious etiologies are excluded and before aggressive immunosuppression is initiated. DAH and ALP carry a mortality rate of 50 % [104, 109]. In patients requiring mechanical ventilation, a lung protective strategy with low tidal volumes should be used. We recommend high-dose intravenous methylprednisone (1 g daily for 72 hours), followed by oral corticosteroids and possibly intravenous cyclophosphamide. In refractory cases of DAH or ALP, plasmapheresis and intravenous immunoglobulins have been described [99, 104]. Success with rituximab has also been reported [109].

Conclusions

CTD-ILD comprises a heterogeneous group of disorders marked by varying degrees of fibrosis and/or inflammation within the lung parenchyma. ILD is a potentially morbid and life-threatening complication of any CTD, but it is most commonly seen in patients with RA, SSc or PM/DM. A large group of patients have features suggestive of CTD, but cannot be classified according to currently available systems. How best to treat them—or other patients with CTD-ILD—is based largely on experience and observational studies. Future research is required to advance understanding of the pathogenesis of CTD-ILD and to help determine which patients require therapy, what drugs to use and how long to use them.

Notes

Acknowledgments

Dr. Swigris is supported in part by a Career Development Award from the NIH (K23 HL092227).

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest. 2010;138(2):251–6. A synopsis and discussion of “lung-dominant connective tissue diseases”, “autoimmune-featured ILD” and “undifferentiated connective tissue diseases” including a proposal for criteria to more accurately capture the group of “lung-dominant CTDs”. PubMedCrossRefGoogle Scholar
  2. 2.
    Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest. 2011;140(5):1292–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Homma Y, Ohtsuka Y, Tanimura K, Kusaka H, Munakata M, Kawakami Y, Ogasawara H. Can interstitial pneumonia as the sole presentation of collagen vascular diseases be differentiated from idiopathic interstitial pneumonia? Respiration. 1995;62(5):248.PubMedCrossRefGoogle Scholar
  4. 4.
    •• Wells AU. Pulmonary function tests in connective tissue disease. Semin Respir Crit Care Med. 2007;28:379–88. Excellent summary on pulmonary function test patterns observed in CTD-ILD. PubMedCrossRefGoogle Scholar
  5. 5.
    Lee H, Kim DS, Yoo B, Seo JB, Rho J, Colby TV, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127:2019–27.PubMedCrossRefGoogle Scholar
  6. 6.
    • Tanaka N, Kim JS, Newell JD, Brown KK, Cool CD, Meehan R, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004;232:81–91. Description of characteristic HRCT-patterns in patients with RA-related ILD. PubMedCrossRefGoogle Scholar
  7. 7.
    Song JW, Do K, Kim M, Jang SJ, Colby TV, Kim DS. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest. 2009;136:23–30.PubMedCrossRefGoogle Scholar
  8. 8.
    Park JH, Kim DS, Park I, Jang SJ, Kitaichi M, Nicholson AG, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175:705–11.PubMedCrossRefGoogle Scholar
  9. 9.
    Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35:1322–8.PubMedCrossRefGoogle Scholar
  10. 10.
    •• King TE Jr, Kim EJ, Kinder BW. Connective tissue diseases. In: King TE, Schwartz M, editors. Interstitial lung disease. 5th ed; 2011. Detailed review of connective tissue disease – related interstitial lung diseases from standard reference textbook for the interstitial lung diseases. Google Scholar
  11. 11.
    Kim EA, Lee KS, Johkoh T, et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics. 2002;22:S151–65.PubMedCrossRefGoogle Scholar
  12. 12.
    •• Hwang JH, Misumi S, Sahin H, et al. Computed tomographic features of idiopathic fibrosing interstitial pneumonia: comparison with pulmonary fibrosis related to collagen vascular disease. J Comput Assist Tomogr. 2009;33:410–5. Comprehensive reviews of radiologic and histopathologic features in CTD-ILD. PubMedCrossRefGoogle Scholar
  13. 13.
    •• Lynch DA. Lung disease related to collagen vascular disease. J Thoracic Imaging. 2009;24(4):299–309. Excellent overview of radiologic, serologic and histopathologic patterns of lung injury from CTD. CrossRefGoogle Scholar
  14. 14.
    Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655–66.PubMedCrossRefGoogle Scholar
  15. 15.
    Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NSL, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962–70.PubMedCrossRefGoogle Scholar
  16. 16.
    Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009 May;337(5):329–35.PubMedCrossRefGoogle Scholar
  17. 17.
    Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well-tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130:30–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Kobayashi A, Okamoto H. Treatment of interstitial lung diseases associated with connective tissue diseases. Expert Rev Clin Pharmacol. 2012;5(2):219–27.PubMedCrossRefGoogle Scholar
  19. 19.
    Hyland RH, Gordon DA, Broder I, Davies GM, Russell ML, Hutcheon MA, et al. A systematic controlled study of pulmonary abnormalities in rheumatoid arthritis. J Rheumatol. 1983;10:395–405.PubMedGoogle Scholar
  20. 20.
    Jurik AG, Davidsen D, Graudal H. Prevalence of pulmonary involvement in rheumatoid arthritis and its relationship to some characteristics of the patients. A radiological and clinical study. Scand J Rheumatol. 1982;11:217–24.PubMedCrossRefGoogle Scholar
  21. 21.
    Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D, Lake FR. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med. 1997;156:528–35.PubMedGoogle Scholar
  22. 22.
    Saag KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW, Schwartz DA. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis. 1997;56:463–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Deane KD, Norris JM, Holers VM. Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum Dis Clin North Am. 2010;36(2):213–41.PubMedCrossRefGoogle Scholar
  24. 24.
    Barrera P, Laan RF, van Riel PL, Dekhuijzen PN, Boerbooms AM, van de Putte LB. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis. 1994;53:434–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Sakai F, Noma S, Kurihara Y, Yamada H, Azuma A, Kudoh S, et al. Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Rheumatol. 2005;15:173–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Scott DL, Bradby GV, Aitman TJ, Zaphiropoulos GC, Hawkins CF. Relationship of gold and penicillamine therapy to diffuse interstitial lung disease. Ann Rheum Dis. 1981;40:136–41.PubMedCrossRefGoogle Scholar
  27. 27.
    Parry SD, Barbatzas C, Peel ET, Barton JR. Sulphasalazine and lung toxicity. Eur Respir J. 2002;19:756–64.PubMedCrossRefGoogle Scholar
  28. 28.
    Thavarajah K, Wu P, Rhew EJ, Yeldandi AK, Kamp DW. Pulmonary complications of tumor necrosis factor-targeted therapy. Respir Med. 2009;103:661–9.PubMedCrossRefGoogle Scholar
  29. 29.
    •• pneumotox.com – Foucher P, Camus P. The drug-induced lung diseases. Very useful online tool that allows searches for individual medications listing all respective drug-induced pulmonary complications described in the literature. Google Scholar
  30. 30.
    Abel T, Andrews BS, Cunningham PH, et al. Rheumatoid vasculitis: Effect of cyclophosphamide on the clinical course and levels of circulating immune complexes. Ann Intern Med. 1980;93:407–13.PubMedGoogle Scholar
  31. 31.
    Chang HK, Park W, Ryu DS. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: A case report. J Korean Med Sci. 2002;17:270–3.PubMedGoogle Scholar
  32. 32.
    Scott DGI, Bacon PA. Resonse to methotrexate in fibrosing alveolitis associated with connective tissue disease. Thorax. 1980;35:725–31.PubMedCrossRefGoogle Scholar
  33. 33.
    • Steen VD. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg. 1998;17:48–54. A comprehensive review of the general clinical features of systemic sclerosis. PubMedCrossRefGoogle Scholar
  34. 34.
    Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum. 2009;60:1831–9.PubMedCrossRefGoogle Scholar
  35. 35.
    • Reveille JD, Solomon DH. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 2003;49:399–412. This article is part of a series on immunologic testing guidelines published by the American College of Rheumatology and HOC Committee on Immunologic Testin. For further details an introduction to this series has been published in Arthritis Care and Research, Vol 47, Nr 4, August 2002 pp 429 –433. PubMedCrossRefGoogle Scholar
  36. 36.
    Bouros D, Wells AU, Nicholson AG, Cobly TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Goh NSL, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248–54.PubMedCrossRefGoogle Scholar
  38. 38.
    Haubitz M, Schellong S, Göbel U, Schurek HJ, Schaumann D, Koch KM, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum. 1998;41:1835–44.PubMedCrossRefGoogle Scholar
  39. 39.
    Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176:1026–34.PubMedCrossRefGoogle Scholar
  40. 40.
    Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344–7.PubMedCrossRefGoogle Scholar
  41. 41.
    • Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403–7. Original description and diagnostic criteria for polymyositis and dermatomyositis by Bohan and Peter. PubMedCrossRefGoogle Scholar
  42. 42.
    Krain L. Dermatomyositis in six patients without initial muscle involvement. Arch Dermatol. 1975;111:241–5.PubMedCrossRefGoogle Scholar
  43. 43.
    • Fathi M, Lundberg IE, Tornling G. Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med. 2007;28:451–8. A comprehensive review of polymyositis and dermatomyositis with emphasis on the pulmonary manifestation. PubMedCrossRefGoogle Scholar
  44. 44.
    • Ikezoe J, Johkoh T, Kohno N, et al. High-resolution CT findings of lung disease in patients with polymyositis and dermatomyositis. J Thorac Imag. 1996;11:250–9. A review of radiological features on chest HRCT in PM/DM. CrossRefGoogle Scholar
  45. 45.
    Schwarz MI. The lung in polymyositis. Clin Chest Med. 1998;19:701–12. viii.PubMedCrossRefGoogle Scholar
  46. 46.
    Won Huh J, Soon Kim D, Keun Lee C, Yoo B, Bum Seo J, Kitaichi M, et al. Two distinct clinical types of interstitial lung disease associated with polymyositis/dermatomyositis. Respir Med. 2007;101:1761–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Tansey D, Wells AU, Colby TV, Ip S, Nikolakoupolou A, du Bois RM, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology. 2004;44:585–96.PubMedCrossRefGoogle Scholar
  48. 48.
    Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M, Cadranel J, Delaval P, Ternamian PJ, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J. 2003;22:245–50.PubMedCrossRefGoogle Scholar
  49. 49.
    Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164:1182–5.PubMedGoogle Scholar
  50. 50.
    Schnabel A, Reuter M, Biederer J, Richter C, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum. 2003;32:273–84.PubMedCrossRefGoogle Scholar
  51. 51.
    Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum. 1996;26:459–67.PubMedCrossRefGoogle Scholar
  52. 52.
    Chen I, Jan Wu Y, Lin C, Fan K, Luo S, Ho H. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol. 2009;28:639–46.PubMedCrossRefGoogle Scholar
  53. 53.
    • Dalakas M, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–82. A comprehensive review of the general clinical features of polymyositis and dermatomyositis. PubMedCrossRefGoogle Scholar
  54. 54.
    Evans J. Antinuclear antibody testing in systemic autoimmune disease. Clin Chest Med. 1998;19:613–25. vii.PubMedCrossRefGoogle Scholar
  55. 55.
    Targoff IN. Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol. 1993;100:116S–23.PubMedCrossRefGoogle Scholar
  56. 56.
    Marie I, Hachulla E, Chérin P, Dominique S, Hatron P, Hellot M, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47:614–22.PubMedCrossRefGoogle Scholar
  57. 57.
    Marie I, Hatron PY, Hachulla E, Wallaert B, Michon-Pasturel U, Devulder B. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol. 1998;25:1336–43.PubMedGoogle Scholar
  58. 58.
    Selva-O’Callaghan A, Labrador-Horrillo M, Muñoz-Gall X, Martínez-Gomez X, Majó-Masferrer J, Solans-Laque R, et al. Polymyositis/dermatomyositis associated lung disease: analysis of a series of 81 patients. Lupus. 2005;14:534–42.PubMedCrossRefGoogle Scholar
  59. 59.
    Imbert-Masseau A, Hamidou M, Agard C, Grolleau JY, Chérin P. Antisynthetase syndrome. Joint Bone Spine. 2003;70:161–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Ando M, Miyazaki E, Yamasue M, Sadamura Y, Ishii T, Takenaka R, Ito T, Nureki S, Kumamoto T. Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol. 2010;29(4):443–5.PubMedCrossRefGoogle Scholar
  61. 61.
    Ochi S, Nanki T, Takada K, Suzuki F, Komano Y, Kubota T, Miyasaka N. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol. 2005;23(5):707–10.PubMedGoogle Scholar
  62. 62.
    Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S, Kurihara Y, Osada H, Satoh M, Ozaki S. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2007;46(1):124.CrossRefGoogle Scholar
  63. 63.
    Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, Amano K, Takeuchi T. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32(9):1719.PubMedGoogle Scholar
  64. 64.
    Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford). 2009;48:968–71.CrossRefGoogle Scholar
  65. 65.
    Lambotte O, Kotb R, Maigne G, Blanc F, Goujard C, Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J Rheumatol. 2005;32:1369–70.PubMedGoogle Scholar
  66. 66.
    Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H, Suda T, Chida K. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009;187(3):201.PubMedCrossRefGoogle Scholar
  67. 67.
    Sjögren H. Zur Kenntnis der keratoconjunctivitis sicca. Acta Ophthalomol. 1933;11(suppl II):1.Google Scholar
  68. 68.
    • Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American –European Consensus Group. Ann Rheum Dis. 2002;61:554–8. Diagnostic criteria for primary and secondary Sjögren’s syndrome following revision by the European Study Group on Classification Criteria for Sjögren’s syndrome. PubMedCrossRefGoogle Scholar
  69. 69.
    Alexander EL, Provost TT, Stevens MB, Alexander GE. Neurologic complications of primary Sjögren’s syndrome. Medicine (Baltimore). 1982;61:247–57.Google Scholar
  70. 70.
    Carine S, Gottenberg JE, Bengoufa D, Desmoulins F, Miceli-Richard C, Mariette X. Anticentromere antibodies identify patients with Sjögren’s syndrome and autoimmune overlap syndrome. J Rheumatol. 2007;34:2253–8.Google Scholar
  71. 71.
    Fischbach M, Char D, Christensen M, et al. Immune complexes in Sjögren’s syndrome. Arthritis Rheum. 1980;23:791–5.PubMedCrossRefGoogle Scholar
  72. 72.
    • Fox R. Sjögren’s syndrome. Lancet. 2005;366:321–31. A comprehensive review of the general clinical features of Sjögren’s syndrome. PubMedCrossRefGoogle Scholar
  73. 73.
    Royer B, Cazals-Hatem D, Sibilia J, Agbalika F, Cayuela JM, Soussi T, et al. Lymphomas in patients with Sjögren’s syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 1997;90:766–75.PubMedGoogle Scholar
  74. 74.
    Papathanasiou MP, Constantopoulos SH, Tsampoulas C, Drosos AA, Moutsopoulos HM. Reappraisal of respiratory abnormalities in primary and secondary Sjögren’s syndrome. A controlled study. Chest. 1986;90:370–4.PubMedCrossRefGoogle Scholar
  75. 75.
    Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87:210–9.CrossRefGoogle Scholar
  76. 76.
    Constantopoulos SH, Papadimitriou CS, Moutsopoulos HM. Respiratory manifestations in primary Sjögren’s syndrome. A clinical, functional, and histologic study. Chest. 1985;88:226–9.PubMedCrossRefGoogle Scholar
  77. 77.
    • Cain HC, Noble PW, Matthay RA. Pulmonary manifestations of Sjögren’s syndrome. Clin Chest Med. 1998;19:687–99. viii. A comprehensive review of the pleuro-pulmonary manifestations of SjS. PubMedCrossRefGoogle Scholar
  78. 78.
    Launay D, Hachulla E, Hatron P, Jais X, Simonneau G, Humbert M. Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore). 2007;86:299–315.CrossRefGoogle Scholar
  79. 79.
    Chen H, Lai S, Kwang W, Liu J, Chen C, Huang D. Middle lobe syndrome as the pulmonary manifestation of primary Sjögren’s syndrome. Med J Aust. 2006;184:294–5.PubMedGoogle Scholar
  80. 80.
    Tavoni A, Vitali C, Cirigliano G, Frigelli S, Stampacchia G, Bombardieri S. Shrinking lung in primary Sjögren’s syndrome. Arthritis Rheum. 1999;42:2249–50.PubMedCrossRefGoogle Scholar
  81. 81.
    • Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH. Interstitial lung disease in primary Sjögren syndrome. Chest. 2006;130:1489–95. A comprehensive overview of interstitial lung diseases in SjS. PubMedCrossRefGoogle Scholar
  82. 82.
    Yamadori I, Fujita J, Bandoh S, Tokuda M, Tanimoto Y, Kataoka M, et al. Nonspecific interstitial pneumonia as pulmonary involvement of primary Sjögren’s syndrome. Rheumatol Int. 2002;22:89–92.PubMedCrossRefGoogle Scholar
  83. 83.
    Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63 Suppl 5:v1–58.PubMedGoogle Scholar
  84. 84.
    Devaraj A, Wells AU, Hansell DM. Computed tomographic imaging in connective tissue diseases. Semin Respir Crit Care Med. 2007;28:389–97.PubMedCrossRefGoogle Scholar
  85. 85.
    Koyama M, Johkoh T, Honda O, Mihara N, Kozuka T, Tomiyama N, et al. Pulmonary involvement in primary Sjögren’s syndrome: spectrum of pulmonary abnormalities and computed tomography findings in 60 patients. J Thorac Imaging. 2001;16:290–6.PubMedCrossRefGoogle Scholar
  86. 86.
    • Honda O, Johkoh T, Ichikado K, Tomiyama N, Maeda M, Mihara N, et al. Differential diagnosis of lymphocytic interstitial pneumonia and malignant lymphoma on high-resolution CT. AJR Am J Roentgenol. 1999;173:71–4. An interesting study comparing HRCT-findings of lymphocytic interstitial pneumonia and malignant lymphoma of the chest to delineate the differentiating features of these two disorders. PubMedGoogle Scholar
  87. 87.
    Cervera R, Khamashta MA, Hughes GR. “Overlap” syndromes. Ann Rheum Dis. 1990;49(11):947.PubMedCrossRefGoogle Scholar
  88. 88.
    • Mosca M, Tani C, Neri C, Baldini C, Bombardieri S. Undifferentiated connective tissue diseases (UCTD). Autoimmun Rev. 2006;6(1):1. Description of “undifferentiated connective tissue diseases” as a distinct disease entity. PubMedCrossRefGoogle Scholar
  89. 89.
    • Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52(2):148. Original description of “mixed connective tissue disease” as a separate disease entity by Sharp et al. PubMedCrossRefGoogle Scholar
  90. 90.
    Bodolay E, Szekanecz Z, Dévényi K, Galuska L, Csípo I, Vègh J, et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford). 2005;44:656–61.CrossRefGoogle Scholar
  91. 91.
    • Prakash UB. Respiratory complications in mixed connective tissue disease. Clin Chest Med. 1998;19:733–46. ix. A comprehensive review of MCTD-related pulmonary complications. PubMedCrossRefGoogle Scholar
  92. 92.
    Sullivan WD, Hurst DJ, Harmon CE, Esther JH, Agia GA, Maltby JD, et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore). 1984;63:92–107.Google Scholar
  93. 93.
    Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum. 2007;56:2092–4.PubMedCrossRefGoogle Scholar
  94. 94.
    Swaak AJ, Nossent JC, Smeenk RJ. Systemic lupus erythematosus. Int J Clin Lab Res. 1992;22:190–5.PubMedCrossRefGoogle Scholar
  95. 95.
    Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993;72:113–24.Google Scholar
  96. 96.
    • Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7. Revised Criteria for the diagnosis of SLE from the Subcommittee for Systemic Lupus Erythematosus Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. PubMedCrossRefGoogle Scholar
  97. 97.
    Fenlon HM, Doran M, Sant SM, Breatnach E. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol. 1996;166:301–7.PubMedGoogle Scholar
  98. 98.
    • Pego-Reigosa JM, Medeiros DA, Isenberg DA. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract Res Clin Rheumatol. 2009;23:469–80. Concise review of the pulmonary manifestations in SLE. PubMedCrossRefGoogle Scholar
  99. 99.
    Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1999;78:167–75.CrossRefGoogle Scholar
  100. 100.
    Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol. 1996;35:248–54.PubMedCrossRefGoogle Scholar
  101. 101.
    Bankier AA, Kiener HP, Wiesmayr MN, Fleischmann D, Kontrus M, Herold CJ, et al. Discrete lung involvement in systemic lupus erythematosus: CT assessment. Radiology. 1995;196:835–40.PubMedGoogle Scholar
  102. 102.
    Sant SM, Doran M, Fenelon HM, Breatnach ES. Pleuropulmonary abnormalities in patients with systemic lupus erythematosus: assessment with high resolution computed tomography, chest radiography and pulmonary function tests. Clin Exp Rheumatol. 1997;15:507–13.PubMedGoogle Scholar
  103. 103.
    Matthay RA, Schwarz MI, Petty TL, Stanford RE, Gupta RC, Sahn SA, et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore). 1975;54:397–409.CrossRefGoogle Scholar
  104. 104.
    Colby TV. Pulmonary pathology in patients with systemic autoimmune diseases. Clin Chest Med. 1998;19:587–612. vii.PubMedCrossRefGoogle Scholar
  105. 105.
    Min JK, Hong YS, Park SH, Park JH, Lee SH, Lee YS, et al. Bronchiolitis obliterans organizing pneumonia as an initial manifestation in patients with systemic lupus erythematosus. J Rheumatol. 1997;24:2254–7.PubMedGoogle Scholar
  106. 106.
    Filipek MS, Thompson ME, Wang P, Gosselin MV, Primack LS. Lymphocytic interstitial pneumonitis in a patient with systemic lupus erythematosus: radiographic and high-resolution CT findings. J Thorac Imaging. 2004;19:200–3.PubMedCrossRefGoogle Scholar
  107. 107.
    Carette S, Macher AM, Nussbaum A, Plotz PH. Severe, acute pulmonary disease in patients with systemic lupus erythematosus: ten years of experience at the National Institutes of Health. Semin Arthritis Rheum. 1984;14:52–9.PubMedCrossRefGoogle Scholar
  108. 108.
    Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore). 1997;76:192–202.CrossRefGoogle Scholar
  109. 109.
    Todd DJ, Costenbader KH. Dyspnoea in a young woman with active systemic lupus erythematosus. Lupus. 2009;18:777–84.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Markus Gutsche
    • 1
  • Glenn D. Rosen
    • 1
  • Jeffrey J. Swigris
    • 2
  1. 1.Interstitial Lung Disease Program, Division of Pulmonary and Critical Care MedicineStanford UniversityStanfordUSA
  2. 2.Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish HealthDenverUSA

Personalised recommendations